Alessandro Aiuti Selected Research

purine

11/2017	Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
10/2012	Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency.
2/2012	Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID.
1/2012	Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency.
6/2011	Purine metabolism, immune reconstitution, and abdominal adipose tumor after gene therapy for adenosine deaminase deficiency.
12/2009	New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy.
10/2009	How I treat ADA deficiency.
10/2009	ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency.
1/2009	Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
1/2009	Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandro Aiuti Research Topics

Disease

37	Severe combined immunodeficiency due to adenosine deaminase deficiency 01/2021 - 05/2002
31	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 01/2021 - 06/2002
16	Wiskott-Aldrich Syndrome 01/2022 - 08/2002
10	Infections 10/2022 - 09/2002
8	Chronic Granulomatous Disease 01/2021 - 01/2009
6	COVID-19 01/2022 - 01/2020
6	Metachromatic Leukodystrophy (Sulfatide Lipidosis) 01/2021 - 08/2013
5	Inflammation (Inflammations) 01/2021 - 10/2016
4	Neoplasms (Cancer) 10/2022 - 07/2007
4	Mucopolysaccharidosis I (Hurler Syndrome) 01/2022 - 01/2017
3	Primary Immunodeficiency Diseases 10/2022 - 03/2015
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 12/2021 - 01/2020
3	Pneumonia (Pneumonitis) 01/2021 - 10/2020
3	Disease Progression 01/2021 - 01/2017
3	Reinfection 02/2013 - 09/2004
2	Mucopolysaccharidoses 01/2022 - 11/2018
2	Hemorrhage 05/2019 - 01/2019
2	Thalassemia 01/2019 - 01/2019
2	Inborn Genetic Diseases (Disease, Hereditary) 01/2019 - 01/2017
2	Hematologic Neoplasms (Hematological Malignancy) 01/2016 - 08/2012
2	Eczema 05/2014 - 09/2008
2	Virus Diseases (Viral Diseases) 11/2005 - 09/2002
1	Bronchiectasis 10/2022
1	Lung Diseases (Lung Disease) 10/2022
1	Colitis 10/2022
1	Paralysis (Palsy) 02/2022
1	Congenital Adrenal Hyperplasia (Hyperplasia, Congenital Adrenal) 11/2021
1	Diabetes Insipidus 11/2021
1	Immunoglobulin G4-Related Disease 01/2021
1	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 01/2021
1	Stroke (Strokes) 01/2021
1	Neurologic Manifestations (Neurological Manifestations) 01/2021
1	Tuberculosis (Tuberculoses) 01/2021
1	Osteopetrosis 01/2021
1	Asymptomatic Infections 01/2021
1	X-Linked Syndrome Enteropathy Polyendocrinopathy Immune Dysregulation 01/2020
1	Cryptorchidism (Undescended Testes) 01/2020
1	Bacterial Infections (Bacterial Infection) 01/2019
1	Viremia 01/2019
1	Wounds and Injuries (Trauma) 01/2019
1	Lymphopenia (Lymphocytopenia) 11/2018
1	Schmid-Fraccaro syndrome 01/2018
1	Cytopenia 01/2018
1	Rare Diseases (Rare Disease) 01/2018

Drug/Important Bio-Agent (IBA)

33	Adenosine DeaminaseIBA 01/2021 - 06/2002
14	purineIBA 11/2017 - 09/2004
10	AutoantibodiesIBA 01/2022 - 02/2012
10	CytokinesIBA 01/2021 - 09/2002
7	EnzymesIBA 01/2019 - 05/2002
6	Proteins (Proteins, Gene)FDA Link 01/2019 - 11/2006
5	pegademase bovine (pegADA)FDA Link 01/2020 - 12/2003
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2020
3	Cerebroside-Sulfatase (Arylsulfatase A)IBA 01/2021 - 08/2013
3	Wiskott-Aldrich Syndrome ProteinIBA 05/2019 - 05/2014
3	Adenosine (Adenocard)FDA LinkGeneric 11/2017 - 04/2008
3	Busulfan (Busulfex)FDA Link 10/2010 - 01/2009
2	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2021 - 10/2016
2	Sirolimus (Rapamycin)FDA Link 01/2020 - 01/2018
2	Iduronidase (alpha-L-Iduronidase)IBA 01/2019 - 01/2017
2	Hemoglobins (Hemoglobin)IBA 01/2019 - 01/2019
2	Immunoglobulin E (IgE)IBA 01/2019 - 11/2018
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2018 - 03/2015
2	HLA Antigens (Human Leukocyte Antigens)IBA 11/2017 - 01/2017
2	ChemokinesIBA 10/2016 - 09/2002
2	AntibodiesIBA 10/2015 - 06/2012
2	Interleukin-2 (IL2)IBA 03/2013 - 09/2002
2	DNA (Deoxyribonucleic Acid)IBA 03/2012 - 09/2002
2	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 07/2007 - 12/2003
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2005 - 09/2002
1	Messenger RNA (mRNA)IBA 02/2022
1	COVID-19 VaccinesIBA 02/2022
1	2019-nCoV Vaccine mRNA-1273IBA 02/2022
1	VaccinesIBA 02/2022
1	Growth Hormone (Somatotropin)IBA 11/2021
1	EmapalumabIBA 01/2021
1	Rituximab (Mabthera)FDA Link 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021
1	Prednisolone (Predate)FDA LinkGeneric 01/2021
1	Immunoglobulin G (IgG)IBA 10/2020
1	InterferonsIBA 10/2020
1	Immunoglobulins (Immunoglobulin)IBA 01/2020
1	Transcription Factors (Transcription Factor)IBA 01/2020
1	IronIBA 01/2019
1	GlobinsIBA 01/2019
1	sofosbuvir drug combination ledipasvirIBA 12/2018
1	GlycosaminoglycansIBA 11/2018
1	Interferon Type IIBA 11/2018
1	AutoantigensIBA 11/2018
1	defibrotideIBA 01/2018

Therapy/Procedure

13	Hematopoietic Stem Cell Transplantation 01/2022 - 05/2007
9	Therapeutics 01/2021 - 09/2002
6	Enzyme Replacement Therapy 01/2022 - 11/2006
5	Transplantation 01/2019 - 03/2007
5	Stem Cell Transplantation 11/2017 - 10/2009
4	Aftercare (After-Treatment) 01/2020 - 01/2012
3	Bone Marrow Transplantation (Transplantation, Bone Marrow) 02/2012 - 12/2009
1	Splenectomy 10/2022
1	Orchiopexy 01/2020
1	Platelet Transfusion (Blood Platelet Transfusions) 05/2019